Oxycodone

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O

InChI

InChIKey=BRUQQQPBMZOVGD-XFKAJCMBSA-N

InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	500.0 nM [EC50]
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	16000.0 nM [EC50]
Delta opioid receptor 81 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2752	4000.0 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Acute and chronic pain 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf	Primary	Approved 8583	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950
Opioid-related disorders 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00158184	Primary	Phase II 1147	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950
Osteoarthritis 157 Sources: https://clinicaltrials.gov/ct2/show/NCT00985621	Primary	Phase III 665	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date 1950

C_max

Value	Dose	Analyte	Population
22.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
39.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
19 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
17.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
15.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
12.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
128.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
268.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
105 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
133 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
113.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
99 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.55 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
3.85 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
2.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
3.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	healthy, 30 years Health Status: healthy Age Group: 30 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	Other AEs: Pulmonary edema... Other AEs: Pulmonary edema Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 1.7%) Dizziness (grade 1-2, 1.7%) Abdominal pain (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Headache, Vomiting... AEs leading to discontinuation/dose reduction: Headache (grade 1-2, 0.8%) Vomiting (grade 1-2, 0.8%) Nausea (grade 1-2, 0.8%) Somnolence (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 6.3%) Dizziness (grade 1-2, 4.8%) Confusion (grade 1-2, 3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Disc. AE: Vomiting, Flu syndrome... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 0.8%) Flu syndrome (grade 1-2, 0.8%) Confusion (grade 1-2, 0.8%) Fatigue (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf
6 mg 2 times / day single, oral Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	healthy, mean age 33 years Health Status: healthy Age Group: mean age 33 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (11.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf	healthy, mean age 36 years Health Status: healthy Age Group: mean age 36 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Nav1.5 116	CYP3A5 446 P-gp 2052 UGT2B7 456 UGT2B4 278	P-gp 301 BCRP 101

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 985	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802418/	yes
P-gp 1932	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	major
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	minor
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 119	inhibitor 2237 Sources: https://europepmc.org/article/med/29722437
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670374/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7852	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7852
ZINC	ZINC000000403533	http://zinc15.docking.org/substances/ZINC000000403533

PubMed

Title	Date	PubMed
Prescription for addiction?	2001 Mar	12400320
Narcotic analgesics for dental pain: available products, strengths, and formulations.	2001 Mar-Apr	12004688
Controlled-release oxycodone hydrochloride (OxyContin).	2001 Sep	11855610
Valdecoxib.	2002	12269850
Oxycodone/ibuprofen.	2002	11881533
Hydromorphone for acute and chronic pain.	2002	11869661
The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid.	2002 Apr	11991534
Oxy's offspring.	2002 Apr 22	11974393
Capillary electrophoresis and capillary electrophoresis-ion trap multiple-stage mass spectrometry for the differentiation and identification of oxycodone and its major metabolites in human urine.	2002 Apr 25	12013227
More blame and praise for a pain drug.	2002 Apr 29	11989324
Severe chronic renal failure in association with oxycodone addiction: a new form of fibrillary glomerulopathy.	2002 Aug	12203209
Minimal interaction between gatifloxacin and oxycodone.	2002 Aug	12162476
Nasal administration of opioids for pain management in adults.	2002 Aug	12139528
Treatment of postherpetic neuralgia: a systematic review of the literature.	2002 Feb	11978209
Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children.	2002 Feb	11882229
The influence of anaesthesia and surgery on the circadian rhythm of melatonin.	2002 Jan	11903069
A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma.	2002 Jan	11866386
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.	2002 Jan	11833838
Perioperative management in children with sickle cell disease undergoing laparoscopic surgery.	2002 Jan-Mar	12002293
Safety and efficacy of controlled-release oxycodone: a systematic literature review.	2002 Jul	12126222
Gateways to clinical trials.	2002 Jul-Aug	12224444
OxyContin and neonatal abstinence syndrome.	2002 Jun	12032797
An evaluation of the efficacy and tolerability of oral tramadol hydrochloride tablets for the treatment of postsurgical pain in children.	2002 Jun	12032009
Comparison of the opioid-sparing efficacy of diclofenac and ketoprofen for 3 days after knee arthroplasty.	2002 Mar	11939925
There is no accounting for accountability.	2002 Mar	11884858
Validity and reliability of three commercially available breath-by-breath respiratory systems.	2002 Mar	11882930
[Chronic pain of the musculoskeletal system. Make your patients move!].	2002 Mar 14	12066520
Pain management after major orthopaedic surgery: current strategies and new concepts.	2002 Mar-Apr	11929206
OxyContin Use and Abuse.	2002 Mar-Apr	11889673
From physician to inmate.	2002 May	12063835
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery.	2002 May	12036167
Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery.	2002 May	12031758
Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery.	2002 May	12027845
Sevoflurane versus halothane: effect of oxycodone premedication on emergence behaviour in children.	2002 May	11982836
A randomized controlled trial of early oral analgesia in gynecologic oncology patients undergoing intra-abdominal surgery.	2002 May	11978276
Venous malformations associated with central pain: report of a case.	2002 Nov	12401626
Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.	2002 Nov	12388636
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.	2002 Oct	12423011
Detection of cocaine analytes and opiates in nails from postmortem cases.	2002 Oct	12423005
Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.	2002 Oct	12422999
Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.	2002 Oct	12422998
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy.	2002 Oct	12373390
Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery.	2002 Oct	12351250
Massive OxyContin ingestion refractory to naloxone therapy.	2002 Oct	12239500
Induced hypothermia for drug overdose.	2002 Sep	12208689
Interscalene brachial plexus block is superior to subacromial bursa block after arthroscopic shoulder surgery.	2002 Sep	12190808
[Pain therapy in rheumatic diseases. Oxycodon is not a weak opioid].	2002 Sep 12	12380334
Paravertebral somatic nerve block compared with peripheral nerve blocks for outpatient inguinal herniorrhaphy.	2002 Sep-Oct	12373694
Review: tricyclic antidepressants, capsaicin, gabapentin, and oxycodone are effective for postherpetic neuralgia.	2002 Sep-Oct	12207430
Oxycontin--misuse and abuse.	2002 Summer	12108125

Patents

Sample Use Guides

In Vivo Use Guide

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.

Route of Administration: Oral

In Vitro Use Guide

Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:36:49 GMT 2025` Edited by `admin` on `Mon Mar 31 17:36:49 GMT 2025`
Record UNII	CD35PMG570
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Oxycodone

Official Name

English

N02AA05

Preferred Name

English

OXYCODONE [HSDB]

Common Name

English

IDS-NO-002

Code

English

oxycodone [INN]

Common Name

English

14-HYDROXYDIHYDROCODEINONE

Common Name

English

OXYCODONE [MI]

Common Name

English

OXYCODONE [VANDF]

Common Name

English

OXYCODONE [MART.]

Common Name

English

OXYCODONE [ORANGE BOOK]

Common Name

English

Oxycodone [WHO-DD]

Common Name

English

OXYCODONE [USAN]

Common Name

English

OXYCODONE CII

Common Name

English

4,5?-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one

Systematic Name

English

(5.ALPHA.)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE

Systematic Name

English

NSC-19043

Code

English

XTAMPZA ER

Brand Name

English

REMOXY

Brand Name

English

PTI-821

Code

English

PAVINAL

Common Name

English

XTAMPZA

Common Name

English

(-)-14-HYDROXYDIHYDROCODEINONE

Common Name

English

OXYMORPHONE 3-METHYL ETHER

Common Name

English

OXYCODONE CII [USP-RS]

Common Name

English

HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D [EP IMPURITY]

Common Name

English

MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, (5.ALPHA.)-

Systematic Name

English

PF-00345439

Code

English

DIHYDRONE

Common Name

English

PTI 821

Common Name

English

Classification Tree Code System Code

WHO-ATC

N02AA56